Company: SMNR
Filing Date: 2025-10-21
Form Type: S-1
Source: 0001193125-25-245178
Chunk: 284

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-10-21
Form: S-1
Chunk 284
---
| • |     | determining and approving engagements of the independent registered public accounting firm, prior to commencement of the engagement, and the scope of and plans for the audit; |

| • |     | monitoring the rotation of partners of the independent registered public accounting firm on Semnur’s audit engagement; |

| • |     | reviewing with management and the independent registered public accounting firm any fraud that includes management or other employees who have a significant role in Semnur’s internal control over financial reporting and any significant changes in internal controls; |

| • |     | establishing and overseeing procedures for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting, auditing or internal control matters; |

| • |     | reviewing the results of management’s efforts to monitor compliance with Semnur’s programs and policies designed to ensure compliance with laws and rules; |

| • |     | overseeing Semnur’s programs, policies and procedures related to Semnur’s information technology systems, information security risk management and information technology risk exposures, and the steps taken to monitor, mitigate and control such exposures and the Company’s plans to mitigate cybersecurity risks and to respond to data breaches; and |

| • |     | reviewing and discussing with management and the independent registered public accounting firm the results of the annual audit and the independent registered public accounting firm’s assessment of the quality and acceptability of Semnur’s accounting principles and practices and all other matters required to be communicated to the Audit Committee by the independent registered public accounting firm |

183

| under generally accepted accounting standards, the results of the independent registered public accounting firm’s review of Semnur’s quarterly financial information prior to public disclosure and Semnur’s disclosures in its periodic reports filed with the SEC. |

Dorman Followwill qualifies as an Audit Committee financial expert within the meaning of SEC regulations and each of Jay Chun, M.D., Ph.D., Dorman Followwill and Yue Alexander Wu, Ph.D. meet the financial sophistication requirements under the Nasdaq Listing Rules. Semnur’s independent registered public accounting firm and Semnur management periodically meet separately with the Audit Committee. The Audit Committee reviews, discusses and assesses its own performance and composition at least annually. The Audit Committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommends any proposed changes to the Board for its consideration and approval. The composition and functioning of the Audit Committee compl